Literature DB >> 8555090

Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia.

J K Burgess1, R Lindeman, C N Chesterman, B H Chong.   

Abstract

Heparin-induced thrombocytopenia (HIT) is mediated by a heparin-dependent antibody/platelet factor 4/heparin complex binding to platelets via the Fc gamma receptor (type IIA). A single base polymorphism at position 131 of Fc gamma RIIA changes the native arginine to histidine. In the presence of murine monoclonal IgG1 the former phenotype (Fc gamma RIIAArg131) is functionally characterized by strong platelet aggregation (high responder) and the latter (Fc gamma RIIAHis131) by poor aggregation (low responder). In the presence of human IgG2 the opposite response is observed. It has recently been shown that the heparin-dependent antibody is predominantly of this subclass. We hypothesize that a relationship exists between Fc gamma RIIAHis131 and the development of HIT. We studied 24 normal individuals and 20 HIT patients using VM58, a murine monoclonal IgG1, to characterize the phenotype by platelet aggregrometry, and PCR products, amplified with primers bordering the Fc gamma RIIA polymorphism and hybridized with oligonucleotide probes specific for the single base mutation, to determine the genotype. The distribution of phenotypes and genotypes in the two populations differed, with a greater prevalence of the Fc gamma RIIAHis131 allele in the HIT patient population. Homozygous Fc gamma RIIAArg131 individuals were absent from this group. We conclude that the presence of the Fc gamma RIIAHis131 allele is associated with a predisposition to HIT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8555090     DOI: 10.1111/j.1365-2141.1995.tb05383.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  Functions of the Fc receptors for immunoglobulin G.

Authors:  B K Flesch; J Neppert
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

Review 3.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; D B Cines
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 4.  Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia.

Authors:  J M Walenga; W P Jeske; H L Messmore
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

5.  IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia.

Authors:  Anand Padmanabhan; Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Mehraboon S Irani; Barbara J Bryant; Jack B Alperin; Thomas G Deloughery; Kevin P Mulvey; Binod Dhakal; Renren Wen; Demin Wang; Richard H Aster
Journal:  Chest       Date:  2017-04-17       Impact factor: 9.410

Review 6.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

7.  Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis.

Authors:  Iván Palomo; Jaime Pereira; Marcelo Alarcón; Gonzalo Díaz; Patricia Hidalgo; Isabel Pizarro; Eric Jara; Patricio Rojas; Guillermo Quiroga; Rodrigo Moore-Carrasco
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 8.  Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

Authors:  K W Mahaffey
Journal:  Curr Cardiol Rep       Date:  2001-09       Impact factor: 2.931

Review 9.  Heparin-induced thrombocytopenia: present and future.

Authors:  Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 10.  Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management.

Authors:  T E Warkentin
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.